<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>352</serviceExecutionTime><Drug id="74185"><DrugName>RG-6125</DrugName><DrugSynonyms><Name><Value>SDP-051</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-cadherin-11 antibody (rheumatoid arthritis/fibrosis), Synovex</Value></Name><Name><Value>RO-7123520</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1048581">Adheron Therapeutics</CompanyOriginator><CompaniesSecondary><Company id="1048581">Adheron Therapeutics</Company><Company id="19446">Roche Holding AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="74185" type="Drug"><TargetEntity id="667173" type="siDrug">H1M1</TargetEntity><TargetEntity id="760614" type="siDrug">SDP-051</TargetEntity></SourceEntity><SourceEntity id="1048581" type="Company"><TargetEntity id="4297586637" type="organizationId">Adheron Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="1127" type="ciIndication"><TargetEntity id="10016642" type="MEDDRA"></TargetEntity><TargetEntity id="D005355" type="MeSH"></TargetEntity><TargetEntity id="-1910566842" type="omicsDisease"></TargetEntity><TargetEntity id="1185" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="6174" type="Action"><TargetEntity id="2534" type="Mechanism">OB-Cadherin Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00244" type="ciTarget"><TargetEntity id="78870859710093" type="siTarget">Cadherin-11</TargetEntity><TargetEntity id="6203" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1127">Fibrosis</Indication><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="6174">Cadherin-11 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="664">Fibrosuppressant</Action></ActionsSecondary><Technologies><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2018-10-30T10:35:34.000Z</LastModificationDate><ChangeDateLast>2018-10-22T00:00:00.000Z</ChangeDateLast><AddedDate>2011-10-21T10:16:05.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="1048581" linkType="Company"&gt;Adheron&lt;/ulink&gt; (formerly Synovex), was developing RG-6125 (SDP-051; presumed to be RO-7123520), a humanized mAb inhibiting  cadherin-11 protein, using &lt;ulink linkID="1096483" linkType="Company"&gt;Abzena&lt;/ulink&gt;'s technology,  for the potential intravenous treatment of rheumatoid arthritis (RA); the company was also investigating the drug for the potential treatment of fibrosis, including pulmonary and skin fibrosis [&lt;ulink linkID="1232356" linkType="Reference"&gt;1232356&lt;/ulink&gt;], [&lt;ulink linkID="1232354" linkType="Reference"&gt;1232354&lt;/ulink&gt;],  [&lt;ulink linkID="1385153" linkType="Reference"&gt;1385153&lt;/ulink&gt;], [&lt;ulink linkID="1514093" linkType="Reference"&gt;1514093&lt;/ulink&gt;], [&lt;ulink linkID="1513901" linkType="Reference"&gt;1513901&lt;/ulink&gt;], [&lt;ulink linkID="1632202" linkType="Reference"&gt;1632202&lt;/ulink&gt;], [&lt;ulink linkID="1730873" linkType="Reference"&gt;1730873&lt;/ulink&gt;], [&lt;ulink linkID="1731279" linkType="Reference"&gt;1731279&lt;/ulink&gt;],  [&lt;ulink linkID="1888922" linkType="Reference"&gt;1888922&lt;/ulink&gt;], [&lt;ulink linkID="1896883" linkType="Reference"&gt;1896883&lt;/ulink&gt;]. In October 2018, Roche reported that RG-6125 had been discontinued [&lt;ulink linkID="2083840" linkType="Reference"&gt;2083840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, a phase II trial in patients with RA was initiated; in October 2018, the trial was ongoing   [&lt;ulink linkID="1888922" linkType="Reference"&gt;1888922&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2016, a double-blind, placebo-controlled, randomized, parallel-assignment, multicenter, phase II trial (&lt;ulink linkID="283214" linkType="Protocol"&gt;NCT03001219&lt;/ulink&gt;; BP39261) was initiated in the US, Europe, Guatemala , Mexico and South  America  to assess the safety and efficacy of the drug as adjunctive therapy in patients (estimated n = 204) with RA who are inadequately responding to standard-of-care (methotrexate and anti-TNF-alpha therapy). The primary endpoints included the percentage of  participants with adverse events and with anti-drug antibodies, both  at  week 36; American College of Rheumatology (ACR) 50 response rate at week 12 and change  from baseline in bone mineral density lumbar spine at week 36 [&lt;ulink linkID="1888922" linkType="Reference"&gt;1888922&lt;/ulink&gt;], [&lt;ulink linkID="1896883" linkType="Reference"&gt;1896883&lt;/ulink&gt;].  In October 2018, the trial was  expected to complete in November 2018 [&lt;ulink linkID="1888922" linkType="Reference"&gt;1888922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2011, Adheron planned to initiate clinical trials in 2011 [&lt;ulink linkID="1232356" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1232354" linkType="Reference"&gt;1232354&lt;/ulink&gt;]. In January 2014, data from a phase I trial which assessed the safety, tolerability and pharmacokinetics of RG-6125 were reported. The drug was found to be safe and well tolerated up to a dose of 10 mg/kg [&lt;ulink linkID="1513901" linkType="Reference"&gt;1513901&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By February 2015, a series of preclinical studies had been conducted that demonstrated its activity in a number of indications including cancer, rheumatoid arthritis, and a range of fibrotic conditions including non-alcoholic steatohepatitis (NASH) [&lt;ulink linkID="1632202" linkType="Reference"&gt;1632202&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2013, data had demonstrated that SDP-051 bound to cadherin-11 on lung and dermal fibroblasts with high affinity [&lt;ulink linkID="1385153" linkType="Reference"&gt;1385153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2011, data from preclinical studies in RA animal models had shown that RG-6125 inhibited swelling and cartilage destruction. It also inhibited human fibroblast-like synoviocytes invasion and enzymes damaging joints, and  decreased the inflammation profile of synoviocytes from  RA patients   [&lt;ulink linkID="1232354" linkType="Reference"&gt;1232354&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1127">Fibrosis</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1048581">Adheron Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-09-12T00:00:00.000Z</StatusDate><Source id="1232356" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048581">Adheron Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-01-08T00:00:00.000Z</StatusDate><Source id="1514093" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048581">Adheron Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1127">Fibrosis</Indication><StatusDate>2013-02-21T00:00:00.000Z</StatusDate><Source id="1385153" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2015-10-31T00:00:00.000Z</StatusDate><Source id="1731279" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1888922" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1888922" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1888922" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1888922" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-12-22T00:00:00.000Z</StatusDate><Source id="1888922" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1127">Fibrosis</Indication><StatusDate>2015-10-31T00:00:00.000Z</StatusDate><Source id="1731279" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00244"><Name>Cadherin-11</Name><SwissprotNumbers><Swissprot>O93319</Swissprot><Swissprot>P55287</Swissprot><Swissprot>P55288</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1169854">Astro Bidco Limited</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="152053" title="Abzena to provide services for Adheron Therapeutics on the evaluation of SDP-051 against rheumatoid arthritis"/><Deal id="156679" title="Roche to acquire Adheron Therapeutics  "/></Deals><PatentFamilies><PatentFamily id="1373787" number="WO-2009089062" title="Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders"/><PatentFamily id="969559" number="WO-2012009631" title="Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Voyageur Bio LLC" id="1067653"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>